Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections.

Sara Alosaimy,Sarah C J Jorgensen,Abdalhamid M Lagnf,Sarah Melvin,Ryan P Mynatt,Travis J Carlson,Kevin W Garey,David Allen,Veena Venugopalan,Michael Veve,Vasilios Athans,Stephen Saw,Christine N Yost,Susan L Davis,Michael J Rybak

OPEN FORUM INFECTIOUS DISEASES（2020）

引用 31|浏览13

暂无评分

摘要

Fourty patients were treated with meropenem-vaborbactam (MEV) for serious Gram-negative bacterial (GNB) infections. Carbapenem-resistant Enterobacteriaceae (CRE) comprised 80.0% of all GNB infections. Clinical success occurred in 70.0% of patients. Mortality and recurrence at 30 days were 7.5% and 12.5%, respectively. One patient experienced a probable rash due to MEV.

查看译文

关键词

carbapenem-resistant Enterobacteriaceae,Gram-negative infections,meropenem-vaborbactam,multidrug-resistant

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要